AOD-9604 peptide with retatrutide is a research-only pairing. Learn how each works, dosing considerations, safety, and why neither is FDA-approved.
AOD-9604 peptide with retatrutide is a pairing that exists in online discussion, not in clinical research. AOD-9604 is a synthetic fragment of human growth hormone that was studied for fat loss, while retatrutide is an investigational triple-receptor weight loss drug in Phase 3 trials. No published study has combined them, and neither is FDA-approved for general human use.
What Is AOD-9604?
AOD-9604 is a 16-amino-acid segment of human growth hormone, specifically the region known as hGH 176-191. Scientists designed it to reproduce the fat-metabolizing portion of growth hormone while avoiding its effects on blood sugar and tissue growth.
Human trials in the 1990s and 2000s produced mixed results. An early study reported weight loss, but a larger Phase 2b trial completed in 2007 failed to meet its weight-loss endpoints. Because of that, AOD-9604 never received regulatory approval anywhere for treating obesity.
The reported peptide aod 9604 benefits in research literature center on lipolysis, the breakdown of stored fat, rather than muscle growth or appetite control. That distinction matters when comparing it to GLP-1 based drugs.
What Is Retatrutide?
Retatrutide is an experimental injectable drug developed by Eli Lilly. It activates three hormone receptors at once: GLP-1, GIP, and glucagon.
In a Phase 2 trial published in 2023, participants with obesity lost an average of about 24% of their body weight at the highest dose over 48 weeks. That result ranks among the largest weight reductions reported for any obesity drug candidate.
Retatrutide is not FDA-approved as of 2025. It remains available only through clinical trials, though Phase 3 studies are ongoing.
AOD-9604 vs Retatrutide: How They Compare
The two compounds differ in nearly every way that matters for research. A table helps clarify the gap.
| Feature | AOD-9604 | Retatrutide |
|---|---|---|
| Class | Synthetic hGH fragment (176-191) | Triple GIP / GLP-1 / glucagon agonist |
| Primary action | Fat metabolism (lipolysis) | Appetite suppression, glucose control, energy expenditure |
| Administration | Subcutaneous injection in research settings | Subcutaneous injection, once weekly |
| FDA status | Not approved for human use | Investigational; not approved |
| Human weight-loss data | Small older studies; later trial missed endpoints | Phase 2 showed roughly 24% weight loss at 48 weeks |
| Research amounts reported | 250-500 mcg per day in older protocols | 1-12 mg per week in trials |
Anyone weighing aod 9604 vs retatrutide should note the evidence gap: retatrutide has large, modern, randomized data, while AOD-9604 has decades-old studies with disappointing results.
Why People Ask About Combining Them
The logic circulating online is that AOD-9604 attacks stored fat while retatrutide reduces appetite and calorie intake, so the two might stack. That is a theory, not a finding.
No clinical trial has tested AOD-9604 and retatrutide together, and no pharmacokinetic data describes how they might interact. Adding an unapproved peptide to an investigational drug also makes it impossible to attribute any side effect to either compound.
Similar questions come up with aod 9604 with tirzepatide, another multi-agonist weight loss drug. The same limitation applies: tirzepatide is approved for certain uses, but no study has combined it with AOD-9604.
AOD-9604 vs Tesamorelin
AOD-9604 is frequently confused with tesamorelin, a growth hormone-releasing hormone analog the FDA approved in 2010 for excess abdominal fat in people with HIV-associated lipodystrophy.
The comparison of aod 9604 peptide vs tesamorelin comes down to approval and mechanism. Tesamorelin raises endogenous growth hormone and has an approved indication; AOD-9604 is a fragment with no approval and no clear clinical role.
Handling and Timing in Research Settings
Researchers often ask how to reconstitute aod-9604 with acetic acid because the peptide dissolves poorly in plain bacteriostatic water. Standard laboratory practice is to use a dilute acetic acid solution, commonly 0.6%, as the initial solvent, then dilute further if needed and refrigerate the vial.
Timing in older protocols was typically once daily, sometimes before food. These are descriptions of published research methods, not instructions for personal use.
Retatrutide is dosed weekly in trials, which raises a practical question about pairing a daily peptide with a weekly injection. No protocol exists for that schedule.
Safety, Sourcing, and Legal Status
AOD-9604 is not FDA-approved for human use in the United States. It is sold as a research chemical, which means it has not been reviewed for purity, sterility, or dosing accuracy.
Retatrutide is not FDA-approved either, and it cannot legally be sold as a compounded or prescription product. Vials marketed as research-grade retatrutide are unregulated and may contain no active ingredient or the wrong amount.
Side effects reported with GLP-1 class drugs include nausea, vomiting, diarrhea, and constipation. Growth hormone fragments like AOD-9604 have a limited human safety database.
Anyone considering either compound should speak with a licensed healthcare professional. Self-administering unapproved peptides carries real risk, including injection-site infections, allergic reactions, and unknown long-term effects.
Bottom Line
AOD-9604 and retatrutide are not interchangeable, and no evidence supports using them together. Retatrutide has strong investigational data behind it, while AOD-9604 has older, mostly negative trial results.
The combination remains a topic of online speculation rather than a researched protocol. People seeking prescription weight loss options should review FDA-approved medications with a clinician.
Frequently Asked Questions
Can you take AOD-9604 and retatrutide together?
No clinical trial has tested AOD-9604 and retatrutide together, and neither compound is FDA-approved for that kind of use. Combining them would be an unstudied experiment, and any side effect could not be clearly attributed to one compound or the other. Talk with a licensed healthcare professional before mixing peptides or weight loss drugs.
Is AOD-9604 FDA-approved?
No. AOD-9604 has never been approved by the FDA for any human indication, and a 2007 Phase 2b trial failed to meet its weight-loss endpoints. It is sold as a research chemical, so purity and sterility are not guaranteed. Anything labeled AOD-9604 for human use is unapproved.
Does retatrutide burn fat the way AOD-9604 does?
Retatrutide works mainly by suppressing appetite and improving glucose control through GLP-1, GIP, and glucagon receptors, while AOD-9604 was studied for direct fat metabolism. Retatrutide produced roughly 24% body weight loss in a Phase 2 trial, far more than any result reported for AOD-9604. The two mechanisms are not equivalent.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.